AU2015311761B2 - Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions - Google Patents

Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions Download PDF

Info

Publication number
AU2015311761B2
AU2015311761B2 AU2015311761A AU2015311761A AU2015311761B2 AU 2015311761 B2 AU2015311761 B2 AU 2015311761B2 AU 2015311761 A AU2015311761 A AU 2015311761A AU 2015311761 A AU2015311761 A AU 2015311761A AU 2015311761 B2 AU2015311761 B2 AU 2015311761B2
Authority
AU
Australia
Prior art keywords
mils
hypoxic
composition
infiltrating lymphocytes
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015311761A
Other languages
English (en)
Other versions
AU2015311761A1 (en
Inventor
Ivan M. Borrello
Kimberly A. Noonan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2015311761A1 publication Critical patent/AU2015311761A1/en
Application granted granted Critical
Publication of AU2015311761B2 publication Critical patent/AU2015311761B2/en
Priority to AU2021200648A priority Critical patent/AU2021200648A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2015311761A 2014-09-04 2015-09-04 Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions Ceased AU2015311761B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021200648A AU2021200648A1 (en) 2014-09-04 2021-02-02 Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462045782P 2014-09-04 2014-09-04
US62/045,782 2014-09-04
US201562186040P 2015-06-29 2015-06-29
US62/186,040 2015-06-29
PCT/US2015/048536 WO2016037054A1 (en) 2014-09-04 2015-09-04 Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021200648A Division AU2021200648A1 (en) 2014-09-04 2021-02-02 Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Publications (2)

Publication Number Publication Date
AU2015311761A1 AU2015311761A1 (en) 2017-04-06
AU2015311761B2 true AU2015311761B2 (en) 2020-11-12

Family

ID=55440392

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015311761A Ceased AU2015311761B2 (en) 2014-09-04 2015-09-04 Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
AU2021200648A Abandoned AU2021200648A1 (en) 2014-09-04 2021-02-02 Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021200648A Abandoned AU2021200648A1 (en) 2014-09-04 2021-02-02 Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Country Status (13)

Country Link
US (7) US9687510B2 (enExample)
EP (2) EP3188740B1 (enExample)
JP (2) JP6865160B2 (enExample)
KR (1) KR20170067751A (enExample)
CN (1) CN107109364A (enExample)
AU (2) AU2015311761B2 (enExample)
CA (1) CA2959994C (enExample)
DK (1) DK3188740T3 (enExample)
ES (1) ES2877108T3 (enExample)
IL (2) IL250746B (enExample)
MX (1) MX391017B (enExample)
PT (1) PT3188740T (enExample)
WO (1) WO2016037054A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
WO2016037054A1 (en) 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
JP2018520679A (ja) 2015-06-29 2018-08-02 ザ・ジョンズ・ホプキンス・ユニバーシティー 免疫チェックポイントキメラ抗原受容体療法
WO2017008019A1 (en) * 2015-07-08 2017-01-12 The Johns Hopkins University Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy
HUE066460T2 (hu) 2016-10-26 2024-08-28 Iovance Biotherapeutics Inc A kriokonzervált tumor infiltráló limfociták restimulációja
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
AU2017382243A1 (en) * 2016-12-22 2019-05-02 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
JP2021516666A (ja) * 2018-03-22 2021-07-08 ウィンドミル セラピューティクス インコーポレイテッド 前立腺がん特異的髄浸潤リンパ球およびその使用
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
US20210338730A1 (en) * 2018-11-05 2021-11-04 Windmil Therapeutics, Inc. Marrow Infiltrating Lymphocytes With Increased Clonality and Uses Thereof
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
MX2021006399A (es) * 2018-11-30 2021-07-15 Windmil Therapeutics Inc Linfocitos infiltrantes de medula osea (mils) que expresan receptores de antigenos quimericos (car), metodo de fabricacion de los mismos y metodo de uso en terapia.
CN114072158A (zh) * 2019-03-22 2022-02-18 温德弥尔治疗公司 肺癌特异性骨髓浸润淋巴细胞及其用途
US20230100744A1 (en) * 2020-02-28 2023-03-30 Windmil Therapeutics, Inc. Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils
WO2022066872A1 (en) * 2020-09-24 2022-03-31 Windmil Therapeutics, Inc. Marrow infiltrating lymphocytes (mils) expressing t cell receptors, methods of manufacturing same, and method of using in therapy
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
WO2025160242A1 (en) * 2024-01-23 2025-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of generating tils from cerebro spinal fluid for leptomeningeal disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3243600A (en) 1999-02-23 2000-09-14 Kathleen S. Carswell Improved method of culturing t cells
US6811788B2 (en) * 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
EP2111231A4 (en) * 2007-02-13 2010-12-15 Univ Northeastern METHOD AND COMPOSITIONS FOR IMPROVING IMMUNE REACTIONS
WO2014085437A2 (en) * 2012-11-27 2014-06-05 The Johns Hopkins University Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
EP2364152A4 (en) * 2008-11-03 2013-02-13 Univ Johns Hopkins METHOD FOR PRODUCING AND USING MARKINFILTRATING LYMPHOCYTES (MILS)
BR112014007947A2 (pt) * 2011-10-03 2017-04-18 Univ Los Andes método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
EP2804625A4 (en) 2012-01-17 2015-10-28 Univ Northeastern METHOD AND COMPOSITIONS FOR THE EXPANSION OF IMMUNOSUPPRESSIVE REGULATORY T CELLS IN VITRO AND USES THEREOF
JP2014090678A (ja) * 2012-11-01 2014-05-19 Ito En Ltd 容器詰野菜汁及び／又は果汁含有飲料及びその製造方法、並びに容器詰野菜汁及び／又は果汁含有飲料の呈味劣化防止方法
WO2016037054A1 (en) 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
AU2017382243A1 (en) * 2016-12-22 2019-05-02 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
JP2021516666A (ja) * 2018-03-22 2021-07-08 ウィンドミル セラピューティクス インコーポレイテッド 前立腺がん特異的髄浸潤リンパ球およびその使用
MX2021006399A (es) * 2018-11-30 2021-07-15 Windmil Therapeutics Inc Linfocitos infiltrantes de medula osea (mils) que expresan receptores de antigenos quimericos (car), metodo de fabricacion de los mismos y metodo de uso en terapia.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOONAN, K. ET AL, "Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors", CANCER RESEARCH, (2005), vol. 65, no. 5, pages 2026 - 2034 *

Also Published As

Publication number Publication date
US20160331781A1 (en) 2016-11-17
US20170266232A1 (en) 2017-09-21
JP2021104048A (ja) 2021-07-26
PT3188740T (pt) 2021-06-23
JP6865160B2 (ja) 2021-04-28
DK3188740T3 (da) 2021-06-07
US9687510B2 (en) 2017-06-27
EP3188740A1 (en) 2017-07-12
US20220016172A1 (en) 2022-01-20
US10406178B2 (en) 2019-09-10
IL250746A0 (en) 2017-04-30
IL276347A (en) 2020-09-30
MX2017002852A (es) 2017-05-30
US10172887B2 (en) 2019-01-08
US20190350982A1 (en) 2019-11-21
WO2016037054A1 (en) 2016-03-10
CA2959994C (en) 2023-04-11
US20170258838A1 (en) 2017-09-14
CA2959994A1 (en) 2016-03-10
US20190298768A1 (en) 2019-10-03
US11406666B2 (en) 2022-08-09
EP3922254A1 (en) 2021-12-15
AU2015311761A1 (en) 2017-04-06
US11160830B2 (en) 2021-11-02
IL276347B (en) 2021-10-31
JP7197213B2 (ja) 2022-12-27
MX391017B (es) 2025-03-21
KR20170067751A (ko) 2017-06-16
EP3188740A4 (en) 2018-05-16
IL250746B (en) 2020-08-31
US20230000919A1 (en) 2023-01-05
CN107109364A (zh) 2017-08-29
JP2017527286A (ja) 2017-09-21
AU2021200648A1 (en) 2021-03-04
ES2877108T3 (es) 2021-11-16
EP3188740B1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
US20230000919A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
CN103756964B (zh) 一种高效扩增cd3-cd56+的自然杀伤细胞培养系统的方法
TW201435087A (zh) 含免疫細胞之組成物的製造方法及癌症治療用組成物
JP5856025B2 (ja) 単球またはｎｋ細胞を入手する方法
JP7792426B2 (ja) 極めて強力なｍ－ｃｅｎｋ細胞及び方法
CN105969731B (zh) 一种利用恶性胸腹水大量制备高杀伤活性til细胞的方法
US20030194395A1 (en) Th1 cell adoptive immunotherapy
AU2009214980B2 (en) Methods of obtaining antigen-specific T cell populations
EP3790958A1 (en) Compositions and methods for culturing and expanding cells
HK40064965A (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
HK1240085B (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
HK1240085A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
HK1240616A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
CN117120596A (zh) 高效的m-cenk细胞和方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired